News and Comments

THERAVANCE: BECAME TEMPTING TO INVESTORS ANR TO ITS PARTNER

  Monday, January 07, 2013

Using scientific skills towards building pipelines of promising products does not guarantee a happy ending for a small biotech firm. Pipelines’ breakthroughs need managements’ capabilities and swiftness of actions, which would walk them through the safest and fastest road towards approvals.  We believe Theravance (THRX) has benefited from both its scientists and management. The firm has come nearer than ever to reaching a happy beginning of substantial growth, or perhaps, a happy ending through acquisition, probably, by its partner GlaxoSmithKline (GSK).  More...


Recent News_and_Comments


Archive


Tags